Pesquisar
Halozyme Therapeutics Inc
HALOAdicionar à lista de desejos
112.450USD
+2.770+2.53%
Fechamento 09-18 16:00（ET）
12.84BValor de mercado
38.10P/L TTM
Desempenho da Receita de Halozyme Therapeutics Inc (HALO)
Atualizado em: 30 de jun de 2026No ano passado, Halozyme Therapeutics Inc gerou US$ 867.84M em seu segmento de melhor desempenho, Royalties. A região United States teve a maior contribuição, com US$ 822.98M no período.
Por Empresa
Receita
Proporção
Anual
Anual
Trimestral
Royalties
Sales of proprietary products
Sales of bulk rHuPH20
Sales-based milestones
Sales of device partnered products
Event-based development and regulatory milestones and other fees
Upfront license fees
Device Licensing and development revenue
ENHANZE
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Royalties
867.84M(62.14%)
570.99M(56.24%)
447.87M(54.01%)
360.48M(54.61%)
203.90M(45.99%)
88.60M(33.11%)
69.90M(35.66%)
Sales of proprietary products
194.61M(13.93%)
166.62M(16.41%)
130.83M(15.78%)
72.85M(11.04%)
23.26M(5.25%)
17.03M(6.36%)
17.00M(8.67%)
Sales of bulk rHuPH20
133.02M(9.52%)
86.33M(8.50%)
115.44M(13.92%)
82.08M(12.43%)
80.96M(18.26%)
38.24M(14.29%)
48.28M(24.64%)
Sales-based milestones
70.00M(5.01%)
30.00M(2.95%)
--(--)
10.00M(1.51%)
50.00M(11.28%)
15.00M(5.61%)
--(--)
Sales of device partnered products
48.81M(3.50%)
50.54M(4.98%)
54.58M(6.58%)
36.10M(5.47%)
--(--)
--(--)
--(--)
Event-based development and regulatory milestones and other fees
47.00M(3.37%)
72.50M(7.14%)
69.00M(8.32%)
59.00M(8.94%)
42.00M(9.47%)
69.50M(25.97%)
5.50M(2.81%)
Upfront license fees
18.47M(1.32%)
27.00M(2.66%)
2.00M(0.24%)
30.00M(4.54%)
42.00M(9.47%)
37.26M(13.93%)
53.00M(27.04%)
Device Licensing and development revenue
16.86M(1.21%)
11.34M(1.12%)
9.53M(1.15%)
9.61M(1.46%)
1.19M(0.27%)
1.25M(0.47%)
1.54M(0.79%)
ENHANZE
--(--)
--(--)
--(--)
--(--)
--(--)
719.00K(0.27%)
768.00K(0.39%)
Por Região
Receita
Proporção
Anual
Anual
Trimestral
United States
Switzerland
Belgium
Japan
All other foreign
United States
Switzerland
Belgium
Ireland
FY2025
FY2024
FY2023
FY2022
United States
822.98M(58.93%)
--(--)
--(--)
--(--)
Switzerland
276.41M(19.79%)
--(--)
--(--)
--(--)
Belgium
217.52M(15.57%)
--(--)
--(--)
--(--)
Japan
46.37M(3.32%)
18.94M(1.87%)
15.10M(1.82%)
47.94M(7.26%)
All other foreign
33.33M(2.39%)
9.53M(0.94%)
19.58M(2.36%)
5.26M(0.80%)
United States
--(--)
690.46M(68.00%)
587.20M(70.81%)
437.99M(66.35%)
Switzerland
--(--)
212.39M(20.92%)
149.02M(17.97%)
166.84M(25.27%)
Belgium
--(--)
84.00M(8.27%)
58.35M(7.04%)
2.09M(0.32%)
Ireland
--(--)
--(--)
--(--)
3.00K(--)